The Scottish Medicines Consortium has today published its
acceptance of guselkumab (Tremfya) as a treatment for severe psoriasis in
Guselkumab (Tremfya) is
recommended to treat severe psoriasis, where people have not had adequate
results from conventional systemic treatments, or
cannot take them. You can read the complete guidance by clicking here.
blocks the activity of interleukin 23 (IL-23), a chemical ’messenger’ in the
immune system that signals other cells to cause inflammation. In people with
psoriasis the immune system is overactive and creates too much inflammation,
which leads to the development of psoriasis symptoms. By blocking IL-23,
Tremfya aims to prevent some of that inflammation from occurring, leading to an
improvement in psoriasis for some people who take it. There is currently
one other biologic medication available that blocks the activity of IL-23
available for people with severe psoriasis, called Stelara (ustekinumab).
The National Institute for Health and Care Excellence (NICE) is
also in the process of appraising guselkumab (Tremfya) to treat severe
psoriasis in England and Wales. NICE recently indicated that it would be
approving the treatment, but the full guidance is expected later in June 2018.
For more information on Tremfya, please click here.